What is the recommended management for invasive ductal carcinoma?

Management of Invasive Ductal Carcinoma

Breast-conserving surgery (wide local excision) with radiation therapy is the preferred treatment for most patients with invasive ductal carcinoma, achieving equivalent survival to mastectomy while preserving the breast. 1, 2

Surgical Management

Primary Surgical Options

• Breast-conserving therapy (BCT) is the treatment of choice for the majority of patients with invasive ductal carcinoma, consisting of wide local excision followed by radiation therapy 2
• Mastectomy is indicated when:
  • Tumor size is large relative to breast size 2
  • Tumor multicentricity is present 2
  • Prior radiation to the chest wall or breast has occurred 2
  • Complete excision with negative margins cannot be achieved 1
  • Patient preference 2

Margin Requirements

• Negative margins of resection are critical for reducing local recurrence risk 1
• For patients with extensive intraductal component (EIC)-positive tumors, if initial margins are positive, re-excision is mandatory 1
• If re-excision margins remain positive and further re-excision is not possible, mastectomy is the preferred treatment 1

Axillary Management

• Sentinel lymph node biopsy (SLNB) is the standard of care rather than full axillary clearance, unless axillary node involvement is proven 2
• Patients with isolated tumor cells (<0.2 mm) in the sentinel node and limited sentinel lymph node involvement undergoing tangential breast irradiation may not require further axillary procedures 2
• Positive axillary nodes do not increase breast recurrence risk when treated with conservative surgery and radiation, unlike mastectomy patients 1

Radiation Therapy

Post-Breast-Conserving Surgery

• Postoperative radiation therapy is strongly recommended after breast-conserving surgery 2
• Boost irradiation provides an additional 50% risk reduction and is indicated for patients with unfavorable risk factors for local control 2
• Shorter fractionation schemes (15-16 fractions with 2.5-2.67 Gy single dose) are validated and generally recommended 2

Post-Mastectomy Radiation

• Recommended for patients with:
  • Four or more positive axillary nodes 2
  • T3-T4 tumors 2
• Should be considered for:
  • One to three positive axillary lymph nodes, especially with additional risk factors 2

Partial Breast Irradiation

• May be considered for patients meeting ALL of the following criteria 2:
  • Age ≥50 years
  • Unicentric, unifocal disease
  • Node-negative
  • Non-lobular breast cancer
  • Tumor size ≤3 cm
  • No extensive intraductal component
  • No lymphovascular invasion
  • Negative margins ≥1 mm

Systemic Adjuvant Therapy

Endocrine Therapy

• All patients with ≥1% estrogen receptor expression should receive endocrine therapy 2
• For premenopausal patients:
  • Tamoxifen is standard 2
  • Ovarian suppression value is not well-defined 2
• For postmenopausal patients:
  • Aromatase inhibitors (AIs) are preferred 2

Chemotherapy

• The decision on adjuvant chemotherapy is based on intrinsic phenotype determined by ER/PgR, HER2, and Ki67 assessment 2
• Adjuvant systemic therapy significantly reduces breast recurrence risk when used with conservative surgery and radiation 1
• In NSABP B-13 trial, 8-year ipsilateral breast recurrence was 2.6% with chemotherapy versus 13.4% without chemotherapy in node-negative ER-negative patients 1

Special Considerations

Invasive Lobular Carcinoma Component

• Patients with invasive lobular cancers are candidates for conservative surgery and radiation, provided the tumor is not diffuse and complete excision with negative margins can be achieved 1
• Under these circumstances, there is no increased risk of breast recurrence compared to invasive ductal carcinoma 1, 3

Histopathologic Features

• Extensive intraductal component (EIC): Not an independent risk factor for local recurrence when margins are negative 1
• Vascular/lymphatic invasion, tumor necrosis, inflammatory infiltrate: Associated with approximately 10-15% risk of breast recurrence at 5 years 1
• High histologic grade: Some series show increased breast recurrence risk, though findings are inconsistent 1
• Histologic subtype: Other than invasive ductal carcinoma does not appear associated with altered breast recurrence risk 1

Genetic Testing and Risk-Reducing Surgery

• Genetic testing should be performed for all patients diagnosed at age ≤50 years, those with triple-negative breast cancer, male breast cancer, strong family history, or known familial mutation 4
• Contralateral risk-reducing mastectomy is strongly recommended for BRCA1/2 pathogenic variants and should be considered for PALB2 mutations 4
• For lower penetrance variants (ATM, CHEK2, BARD1, RAD51), intensified surveillance with regular examination and annual mammogram/MRI is recommended 4